Energy & Endurance
NAD+
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Mitochondrial Longevity
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 100, 500 mg
Dosing window: Morning
Receptor / target: Cellular Coenzyme
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 50 mg | Inject once daily subcutaneously. |
| Week 2 | 75 mg | Inject once daily subcutaneously. |
| Weeks 3-8 | 100 mg | Inject once daily subcutaneously. |
| Weeks 9-12 | 100 mg | Inject once daily subcutaneously. |
| Weeks 13-16 | 100 mg | Inject once daily subcutaneously. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative: Aggressive Loading
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-7 | 200mg - 250mg daily | Clinical loading protocol to rapidly restore NAD levels. |
| Week 2+ | 50mg daily | Drop to standard maintenance dose. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 50mg 1x Daily twice a week | |
| Week 2 | 75mg 1x Daily twice a week | |
| Weeks 3-6 | 75mg 1x Daily four times a week | |
| Weeks 7-8 | 100mg 1x Daily four times a week | |
| Weeks 9-12 | 100mg 1x Daily |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (Cellular Coenzyme); route Subcutaneous; timing Morning. Limited-evidence dosing tables are hypotheses, not recommendations. NAD+ protocol logic should separate energy/metabolic support from anti-aging hype. The goal is symptom or marker support, not age reversal, and the main filters are tolerance, flushing/nausea, methylation context, cancer history, and whether precursors or lifestyle basics already cover the need.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active malignancy: NAD+ is the essential energy and DNA repair substrate for all cells including cancer cells; NAD+ supplementation in an active cancer context fuels the Warburg metabolism of tumor cells and enhances the PARP-mediated DNA repair that helps cancer cells evade chemotherapy and radiation-induced DNA damage. Limited / unverified
- Concurrent chemotherapy or radiation therapy: PARP is the primary target of PARP-inhibitor chemotherapy agents (olaparib, niraparib); providing excess NAD+ substrate to the tumor's PARP enzymes directly opposes the mechanism of these agents. Limited / unverified
- Known hypersensitivity to NAD+ or formulation excipients. Limited / unverified
- Severe hypotension: NAD+ has mild vasodilatory effects; subjects with baseline hypotension should inject slowly and remain supine. Limited / unverified
- Pregnancy: safety of supraphysiological NAD+ supplementation during fetal development is not established; the Preiss-Handler and Kynurenine synthesis pathways that regulate NAD+ biosynthesis have specific roles in early embryonic development. Limited / unverified
- Breastfeeding: no data. Limited / unverified
- Subjects on PARP inhibitor chemotherapy: exogenous NAD+ directly antagonizes the mechanism of PARP inhibitor drugs. Limited / unverified
- Severe cardiovascular instability: rapid NAD+ injection can trigger vagal response with chest tightness and nausea; unstable cardiac subjects should not use rapid injection protocols. Limited / unverified
Side effects (limited evidence)
- Intense burning and cramping at the injection site: the defining and most universally reported adverse effect of injectable NAD+; caused by osmotic gradient formation and adenosine purinergic receptor activation at the injection site; intensity is directly rate-dependent: slower injection dramatically reduces pain; the subcutaneous route generally produces less burning than IV but is still significant at full doses. Limited / unverified
- Chest tightness or pressure: occurs with rapid injection; a vagal response to the acute NAD+ pulse; not a sign of cardiac event; resolves immediately upon slowing the injection rate; subjects should always inject slowly (over 2-5 minutes for subcutaneous, longer for IV). Limited / unverified
- Nausea: associated with rapid injection or higher loading doses; vagally mediated. Limited / unverified
- Flushing and sensation of warmth: NAD+ and its metabolites have mild vasodilatory effects; facial and truncal flushing within minutes of injection; typically transient. Limited / unverified
- Headache: reported in a significant minority of users, particularly with early doses; possibly related to cerebral vasodilation and NAD+ pathway flux. Limited / unverified
- Dizziness: vasodilation-related; particularly in the first minutes post-injection. Limited / unverified
- Fatigue in the immediate post-injection period: paradoxical given the energy restoration goal; a transient cellular metabolic reorganization response; typically resolves within 1-2 hours. Limited / unverified
- Insomnia: if administered in the afternoon or evening; sirtuin activation and mitochondrial biogenesis stimulation creates a wakefulness effect; mandatory morning dosing protocol exists specifically to prevent this. Limited / unverified
- Mild anxiety or jitteriness: reported in sensitive subjects at higher doses; related to CNS NAD+ restoration and noradrenergic pathway activation. Limited / unverified
- Potential CD38 activation: at sustained high NAD+ concentrations, CD38 may be upregulated as a homeostatic counter-regulation; this can paradoxically increase NAD+ consumption; not well characterized at subcutaneous doses. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.